Evidence map›Paper›PMID 42683068›Full record

ArticleIranian journal of basic medical sciences2026

Comparative analysis of second and third-generation nanobody-based CAR-NK cells targeting PSMA in prostate cancer immunotherapy:

Masoud Gandomkar Ghalhar, Arezoo Karami Vandishi, Akram Ramazani, Fatemeh Hajari Taheri, Zahra Sharifzadeh, Mohsen Abolhassani, Masoud Soleimani, Niloofar Taghipour, Wytske M van Weerden, Mojgan Bandehpour and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Masoud Gandomkar GhalharDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arezoo Karami VandishiDepartment of Tissue Engineering and Applied Cell Science, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Akram RamazaniDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fatemeh Hajari TaheriFood and Drug Laboratory Research Center (FDLRC), Iran Food and Drug Administration (IFDA), MOH & ME, Tehran, Iran.
Zahra SharifzadehHybridoma Lab, Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Mohsen AbolhassaniHybridoma Lab, Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Masoud SoleimaniDepartment of Tissue Engineering and Applied Cell Science, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Niloofar TaghipourDepartment of Tissue Engineering and Applied Cell Science, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Wytske M van WeerdenDepartment of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
Mojgan BandehpourCellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahmoud HassaniMedical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Kowsar BagherzadehEye Research Center, Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The use of CAR technology in the treatment of cancer cells is progressing, as well as the use of CAR T-cell in the treatment of blood malignancies is in the clinical trial stage. In this study, have compared the second and third generation CAR expressed in NK cells in dealing with prostate cancer cells. Materials and Methods: To optimize the CAR design for detection of NK-92 cells, an Results: Computational analysis indicated that the NB/Flag/hinge configuration would provide superior PSMA recognition. Flow cytometry confirmed successful CAR expression in 47% of second-generation and 49% of third-generation NK-92 cells. Upon co-culture with PSMA-positive LNCaP cells and PSMA-negative PC-3 cells, the third-generation CAR NK cells demonstrated a noticeably stronger cytotoxic effect. Furthermore, higher levels of IL-2, TNF-α, and IFN-γ secretion were observed in the third-generation CAR group compared to the second. Conclusion: According to the computational studies, NB/Flag/hinge interacts with PSMA primarily through electrostatic forces. More importantly, third-generation CAR NK cells targeting PSMA displayed enhanced cytotoxicity and cytokine production relative to second-generation counterparts, pointing to their greater potential for therapeutic application.

Indexed as

Chimeric antigen receptorMolecular dynamics simulationNatural killer cellOX40 co-stimulatory domainProstate-specific membrane antigen (PSMA)Prostatic neoplasmsSingle-domain antibodies (Nanobodies)

Identifiers

PMID42683068
PMCPMC13532051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.